Continuing Medical Education (CME)
HCV Treatment: Incorporating Glecaprevir/Pibrentasvir and Sofosbuvir/Velpatasvir/Voxilaprevir Into Clinical Practice
Credit: .25 AMA PRA Category 1 Credit™
Andrew Muir, MD
This 15-minute activity features a brief video introduction by faculty expert Dr. Muir in which he discusses how the new combination therapies glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir have changed the treatment landscape. The activity then continues with a text-based review of the recent advances in direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) and the clinical trials that led to the approval of these new agents.
In collaboration with